Pfizer (PFE) Other Operating Expenses (2010 - 2017)

Pfizer (PFE) has reported Other Operating Expenses for 8 consecutive years, with -$7.1 billion the latest figure, recorded in Q4 2017.

• On a quarterly basis, Other Operating Expenses rose 10.9% year-over-year to -$7.1 billion in Q4 2017; TTM through Sep 2018 was -$7.1 billion, a 70.72% increase from a year earlier, with the FY2017 full-year figure at -$23.3 billion, up 5.31% from the prior year.
• Other Operating Expenses was -$7.1 billion for Q4 2017 at Pfizer, down from -$5.6 billion in the prior quarter.
• Over five years, Other Operating Expenses peaked at $1.1 billion in Q2 2013 and troughed at -$7.9 billion in Q4 2016.
• A 5-year average of -$3.9 billion and a median of -$5.2 billion in 2016 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses surged 255.52% in 2013 and tumbled 9784.91% in 2015, its largest moves.
• Over 5 years, Other Operating Expenses stood at $18.0 million in 2013, then soared by 194.44% to $53.0 million in 2014, then slumped by 14730.19% to -$7.8 billion in 2015, then slipped by 2.46% to -$7.9 billion in 2016, then climbed by 10.9% to -$7.1 billion in 2017.
• The last three Other Operating Expenses figures came in at -$7.1 billion (Q4 2017), -$5.6 billion (Q4 2017), and -$5.4 billion (Q3 2017), per Business Quant data.